Inhibition of CPT-1 activity with specific agents, such as etomoxir, in animal models resulted in decreased epidermal thickness and reduced KC proliferation, highlighting CPT-1 as a promising metabolic target in psoriasis [156]. The gene discussed is CALCA; the disease is psoriasis.